Format

Send to

Choose Destination
Eur J Pharmacol. 2018 Jan 5;818:271-277. doi: 10.1016/j.ejphar.2017.10.054. Epub 2017 Oct 28.

Anti-migraine effect of ∆9-tetrahydrocannabinol in the female rat.

Author information

1
Graduate Program in Neuroscience, Washington State University, Pullman, WA, USA. Electronic address: ram_kandasamy@wsu.edu.
2
Department of Psychology, Washington State University Vancouver, Vancouver, WA, USA.
3
Department of Psychology, Washington State University, Pullman, WA, USA; Translational Addiction Research Center, Washington State University, Pullman, WA, USA.
4
Graduate Program in Neuroscience, Washington State University, Pullman, WA, USA; Department of Psychology, Washington State University Vancouver, Vancouver, WA, USA; Translational Addiction Research Center, Washington State University, Pullman, WA, USA.

Abstract

Current anti-migraine treatments have limited efficacy and many side effects. Although anecdotal evidence suggests that marijuana is useful for migraine, this hypothesis has not been tested in a controlled experiment. Thus, the present study tested whether administration of ∆9-tetrahydrocannabinol (THC) produces anti-migraine effects in the female rat. Microinjection of the TRPA1 agonist allyl isothiocyanate (AITC) onto the dura mater produced migraine-like pain for 3h as measured by depression of home cage wheel running. Concurrent systemic administration of 0.32 but not 0.1mg/kg of THC prevented AITC-induced depression of wheel running. However, 0.32mg/kg was ineffective when administered 90min after AITC. Administration of a higher dose of THC (1.0mg/kg) depressed wheel running whether rats were injected with AITC or not. Administration of a CB1, but not a CB2, receptor antagonist attenuated the anti-migraine effect of THC. These data suggest that: 1) THC reduces migraine-like pain when administered at the right dose (0.32mg/kg) and time (immediately after AITC); 2) THC's anti-migraine effect is mediated by CB1 receptors; and 3) Wheel running is an effective method to assess migraine treatments because only treatments producing antinociception without disruptive side effects will restore normal activity. These findings support anecdotal evidence for the use of cannabinoids as a treatment for migraine in humans and implicate the CB1 receptor as a therapeutic target for migraine.

KEYWORDS:

Antinociception; Headache; Marijuana; Pain-depressed behavior; Wheel running

PMID:
29111112
PMCID:
PMC5742305
[Available on 2019-01-05]
DOI:
10.1016/j.ejphar.2017.10.054
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center